<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03584204</url>
  </required_header>
  <id_info>
    <org_study_id>SLIM</org_study_id>
    <nct_id>NCT03584204</nct_id>
  </id_info>
  <brief_title>Skeletal Muscle Parameters of Liver Cirrhosis in Non-invasive Imaging and Outcome</brief_title>
  <acronym>SLIM</acronym>
  <official_title>Role of Skeletal Muscle Parameters in Imaging Analysis in the Prediction of Outcome in Patients With Liver Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bonn</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Roma La Sapienza</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Bonn</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The principal aim of this study is to analyse L3-SMI (skeletal muscle index) in a cohort of
      patients with decompensated liver cirrhosis and TIPS (transjugular intrahepatic portosystemic
      shunt), and compare the prognostic power with TPMT (transverse psoas muscle thickness).
      Furthermore, the role of myosteatosis, determined in CT by L3-SMI, MRI and ultrasound will be
      studied.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The principal aim of this study is to analyse L3-SMI (skeletal muscle index) in a cohort of
      patients with decompensated liver cirrhosis and TIPS (transjugular intrahepatic portosystemic
      shunt), and compare the prognostic power with TPMT (transverse psoas muscle thickness).
      Furthermore, the role of myosteatosis, determined in CT by L3-SMI, MRI and ultrasound will be
      studied.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">August 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Survival time</measure>
    <time_frame>up to 60 months</time_frame>
    <description>time of survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to clinical acute decompensations</measure>
    <time_frame>up to 60 months</time_frame>
    <description>time to occurrence of acute decompensations of liver cirrhosis (readmissions, hepatic encephalopathy, bleeding, ascites, hepatorenal syndrome, infections)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to clinical acute-on-chronic liver failure</measure>
    <time_frame>up to 60 months</time_frame>
    <description>acute-on-chronic liver failure according to EASL-CLIF-C definition (grade 1 (best) to 3 (worst)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of sarcopenia</measure>
    <time_frame>up to 60 months</time_frame>
    <description>Assessment of sarcopenia according to EASL-guideline</description>
  </secondary_outcome>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Liver Cirrhosis</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>imaging</intervention_name>
    <description>computed tomography, magnetic resosnance imaging, ultrasound</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with liver cirrhosis of any etiology and CT scan available
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  liver cirrhosis of any etiology

          -  CT scan available

        Exclusion Criteria:

          -  HCC or any malignant disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Praktiknjo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bonn</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Praktiknjo, MD</last_name>
    <phone>+49228 287 15770</phone>
    <email>michael.praktiknjo@ukbonn.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Johannes Chang, MD</last_name>
    <phone>+49228 287 15770</phone>
    <email>johannes.chang@ukbonn.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Bonn</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Praktiknjo, MD</last_name>
      <phone>+49228 28715770</phone>
      <email>michael.praktiknjo@ukbonn.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonel Trebicka, MD, PHD</last_name>
      <email>jonel.trebicka@kgu.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sapienza University of Rome</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuela Merli, Prof.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 8, 2018</study_first_submitted>
  <study_first_submitted_qc>July 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2018</study_first_posted>
  <last_update_submitted>May 19, 2020</last_update_submitted>
  <last_update_submitted_qc>May 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Bonn</investigator_affiliation>
    <investigator_full_name>Michael Praktiknjo</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>sarcopenia</keyword>
  <keyword>cirrhosis</keyword>
  <keyword>transjugular intrahepatic portosystemic shunt</keyword>
  <keyword>TIPS</keyword>
  <keyword>acute-on-chronic liver failure</keyword>
  <keyword>ACLF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

